Bayerische Motoren Werke ADR (BMWYY)

Earth Science Tech (OTC: ETST) was featured on the latest episode of The BioMedWire Podcast released by IBN, with Chairman and CEO Giorgio R. Saumat outlining the company’s vertically integrated healthcare model spanning telehealth and compounding pharmaceuticals, its cash-flow-positive operations and strong balance sheet, and preparations for a potential uplist. During the interview, Saumat highlighted the company’s profitability, limited debt and 2025 diversification initiatives, as Earth Science Tech positions to scale operations in 2026 while IBN continues expanding its specialized content distribution platform.

Telomir Pharmaceuticals (NASDAQ: TELO) announced new in vitro data showing that Telomir-1 (Telomir-Zn) induced broad tumor cell mortality across biologically distinct subtypes of triple-negative breast cancer, with iron-rescue experiments confirming the effect is iron-dependent and linked to the drug’s proposed intracellular metal-modulating mechanism. The company said supplemental iron significantly attenuated tumor cell mortality, supporting that Telomir-Zn reduces labile redox-active iron while increasing zinc availability, targeting the elevated iron levels and oxidative stress observed in many triple-negative breast cancer tumors.

Nutriband (NASDAQ: NTRB) announced it has entered into an exclusive distribution agreement with Costa Rica-based Innomedica for AVERSA Fentanyl, upon approval, and all sports tape products manufactured at its Pocono Pharmaceutical/Active Intell subsidiary. Under the agreement, Innomedica will oversee and finance regulatory approvals as the products advance toward launch. Nutriband’s AVERSA abuse-deterrent transdermal technology is designed to incorporate aversive agents into patches to deter abuse, diversion and misuse of drugs with abuse potential, supported by a broad international patent portfolio.

BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) ( Profile ), which holds multiple clinical-stage and late-stage programs across oncology and central nervous system (“CNS”) indications, into focus as strategic assets aligned with current M&A priorities. The company just announced key advancements in its global intellectual property portfolio supporting OT-101, its proprietary TGF-β antisense therapeutic platform. The advancements strengthen protection across neurology, oncology and central nervous system (“CNS”) drug delivery designed to delivery drugs into the brain by getting through the blood brain barrier. This M&A trend bolsters Oncotelic Therapeutics’ position in the oncology and CNS sectors as the OTLC joins other companies focused on the space, including Arrowhead Pharmaceuticals Inc . (NASDAQ: ARWR), MeiraGTx Holdings plc (NASDAQ: MGTX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN) and…

Phoenix, AZ - A family-owned auto repair shop on West Cactus Road has quietly built a reputation that speaks louder than any billboard. Since 1997, J-N-J Auto Service has been the go-to destination for Phoenix drivers who want straight answers and dependable results. The shop, staffed by ASE-certified technicians, handles everything from routine car maintenance to complex engine diagnostics across all domestic and import makes and models.

Garmin is a high-quality, quietly dominant business trading at a reasonable valuation.

Earth Science Tech (OTC: ETST) is redefining the traditional holding company model by building a diversified portfolio designed for long-term sustainability. Unlike passive investment vehicles, ETST takes an active role in its subsidiaries, utilizing hands-on management and disciplined execution to enhance performance across the board.

A groundbreaking study led by a pair of researchers from Israel and involving research teams in several countries has discovered why some forms of breast cancer metastasize into the brain and become deadly. Their findings could open new doors in the management of breast cancer and address the needs of patients who are at a higher risk of developing metastases in the brain.

OSLO, Norway — Tesla, Inc. (NASDAQ: TSLA) is facing a historic reckoning in the European theater as registration data for the first quarter of 2026 reveals a catastrophic collapse in demand across its most critical strongholds. Once the undisputed king of the electric vehicle (EV) revolution, the Austin-based automaker is now

As of February 12, 2026, Unity Software (NYSE: U) stands at a critical crossroads. Once the undisputed king of mobile game development, the company is currently navigating the most significant "rebuild" in its history. After a tumultuous 2023 and 2024 defined by leadership changes and a pricing scandal that nearly broke the brand, Unity has [...]

Many times, a diagnosis of lung cancer comes late because the early symptoms may be dismissed since they are so subtle and can be mistaken for other illnesses. However, as with any other cancer, catching lung cancer early offers the best chance of getting better treatment outcomes. We explore some of those early warning signs that you may be downplaying.

Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence to accelerate oncology drug discovery and development, announced that Chief Executive Officer and President Panna Sharma will present at the 7th Glioblastoma Drug Development Summit, taking place Feb. 17–19, 2026, in Boston. During a Day Two presentation on Feb. 19, Mr. Sharma will highlight how the Company’s RADR® AI and machine learning platform supported the development of STAR-001, a brain-penetrant therapeutic candidate, including insights into mechanism of action, biomarker identification, indication selection, and novel combination strategies for aggressive CNS cancers such as glioblastoma and ATRT.

Today, February 10, 2026, Harley-Davidson, Inc. (NYSE: HOG) finds itself at a defining crossroads. Long the undisputed symbol of American heavy-metal rebellion, the "Motor Company" is currently navigating a painful but necessary structural reset. After a five-year strategic cycle known as the "Hardwire," which focused on high-margin heavyweight touring bikes, the company has entered 2026 [...]

From lab research to clinical application, photodynamic therapy (“PDT”) is emerging as a powerful treatment approach that uses light and chemistry to selectively target diseased tissue. As this modality gains attention for its precision and safety profile, Soligenix (NASDAQ: SNGX) is developing light-activated therapies designed to treat cutaneous T-cell lymphoma (“CTCL”) and other inflammatory skin diseases using targeted photodynamic mechanisms that aim to improve outcomes while minimizing systemic toxicity.

While people have been quick to blame health insurers for the skyrocketing cost of health care in the U.S., the reality of the situation is more nuanced, and other factors have played a much bigger role in driving up costs. We explore some of those less-reported drivers of the high cost of health care in the country.

Earth Science Tech (OTC: ETST), a strategic holding company focused on acquiring and scaling high-potential operating businesses, announced that it will report financial results for the three months ended Dec. 31, 2025, after the close of trading on Tuesday, Feb. 17, 2026.

The company plans to fix software issues through free over-the-air updates, bringing affected vehicles to Aspen 3.5.6, Alder 2.1.0, or newer versions.

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics using proprietary intranasal delivery technology, today outlined targeted milestones for 2026 as it advances ONP-002, a novel intranasal neurosteroid, toward Phase 2 clinical development. The Company is preparing to initiate a Phase 2a clinical trial of ONP-002 in Australia for the treatment of concussion and mild traumatic brain injury (mTBI), positioning the candidate as a potential first-in-class pharmacological therapy for a large and underserved global market following positive preclinical and Phase 1 safety and efficacy results.

The geopolitical landscape was rocked in early 2026 by the so-called "Greenland Episode," a diplomatic and economic confrontation that has pushed the relationship between the United States and the European Union to its lowest point in decades. What began as a renewed U.S. strategic interest in the Arctic territory

In a landmark shift for the robotics industry, Boston Dynamics has officially transitioned its iconic Atlas robot from a research prototype into a fully autonomous, production-ready workforce. Unveiled in its final commercial form at CES 2026, the all-electric Atlas has shed its hydraulic past and "viral stunt" reputation in favor of sophisticated reinforcement learning (RL) [...]

As the first quarter of 2026 unfolds, the financial markets are navigating a paradoxical landscape defined by aggressive fiscal expansion and unprecedented geopolitical friction. While the "Stampeding Bull" of 2024 and 2025 was driven by a frenzy of price-to-earnings expansion and artificial intelligence (AI) hype, a new narrative has taken

On February 6, 2026, the semiconductor landscape witnessed a jarring recalibration as Qualcomm Incorporated (NASDAQ: QCOM) shares plummeted 8.5% in a single trading session. The catalyst for this sharp correction was not a failure of innovation or a loss of market share, but rather a "structural bottleneck" described by management during their Q1 fiscal 2026 [...]

A planned preclinical study testing a light-activated therapy that helps to kill residual brain cancer cells after a patient has undergone surgery to remove a tumor has elicited excitement as it could provide a way forward in eliminating microscopic cancer tissue that surgeons are unable to see while surgically removing a cancerous tumor from the brain.

TransCode Therapeutics (NASDAQ: RNAZ) announced the submission of an Investigational New Drug (“IND”) application amendment to the U.S. Food and Drug Administration for a planned Phase 2a clinical trial of its lead candidate, TTX-MC138, to be conducted by Quantum Leap Healthcare Collaborative within the PRE-I-SPY program. The dose-expansion study is expected to enroll up to 45 colorectal cancer patients who have completed standard curative-intent therapy and test positive for circulating tumor DNA (“ctDNA”), a marker associated with minimal residual disease (“MRD”) and cancer recurrence, with the trial planned to begin in the first half of 2026 under the leadership of Dr. Paula Pohlmann of MD Anderson Cancer Center.

Telomir Pharmaceuticals (NASDAQ: TELO) announced new cellular study results showing that Telomir-1, administered as Telomir-Zn, induces a rapid and coordinated redistribution of intracellular metals, simultaneously increasing zinc levels while reducing redox-active ferrous iron in living cells. The company said the findings extend its previously reported iron-reduction data by demonstrating, for the first time, a coupled intracellular metal-modulating mechanism rather than simple extracellular chelation, supporting a potential upstream approach to addressing oxidative stress, mitochondrial dysfunction, epigenetic instability, and genomic damage associated with cancer and aging.